EU/3/10/740

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2014 on request of the Sponsor.

On 10 June 2010, orphan designation (EU/3/10/740) was granted by the European Commission to Æterna Zentaris GmbH, Germany, for perifosine for the treatment of multiple myeloma.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Perifosine
Disease / condition
Treatment of multiple myeloma
Date of first decision
10/06/2010
Outcome
Withdrawn
EU designation number
EU/3/10/740

Sponsor's contact details

Æterna Zentaris GmbH
Weismuellerstr. 50
60314 Frankfurt Main
Germany
Tel. + 49 6942 6023475
Fax + 49 6942 6023404
E-mail: info@aezsinc.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating